Manufacturers of gastric balloons used to treat obesity are defending their products’ safety in the wake of an Aug. 10 FDA letter informing providers that multiple deaths had been linked to the products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?